BTA test

Bladder tumour antigen test. A qualitative, point-of-care test that identifies a human complement factor H-related protein, which is produced by several human bladder cell lines but not by non-malignant epithelial cell lines. It has a claimed sensitivity comparable to that of cytology for high-grade tumours and claimed to be better than cytology for low-grade tumours.

References in periodicals archive ?

17] To understand the nuances of the BTA test and the urine cytology test in diagnosis, we conducted a systematic review of published findings and used meta-analysis techniques to quantitatively combine results.

Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis

A significant interaction was observed between exercise and medication use based on results of the BTA test and the Digit Span Forward and Backward Task.

Some cognitive function in Parkinson's improves with exercise

Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.

Complement factor H as a marker for detection of bladder cancer

Because original BTA test sensitivity (approximately 40%) was no better than that of cytology, several assay modifications were introduced, including the BTA stat and BTA TRAK.

BLADDER CANCER MARKERS: Current availability and the future standard of care

He has also served as President and CEO of Bard Diagnostics (formerly Bainbridge Sciences), a pioneering cancer diagnostics company that developed and launched the BTA test, the first diagnostic test for bladder cancer approved by the U.

LifeSpex Appoints New CEO; Healthcare Executive Will Lead Approval and Launch of CerviScan

3,4] A number of novel immunoassays for cancer-associated proteins in voided urine have been investigated as diagnostic tool to replace cytology, including BTA test, BTA Stat test, NMP22 and Immunocyt.

A pilot study of urinary microRNA as a biomarker for urothelial cancer

The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder.

Current concepts in biomarker technology for bladder cancers

The new, rapid BTA stat test is even simpler to perform and improves upon the original Bard BTA Test.

Revolutionary new test for bladder cancer receives FDA clearance

The Bard BTA Test takes three minutes to perform and, at about $17 per test for the laboratory, it is approximately one third of the cost of voided urine cytology, the conventional noninvasive test for bladder cancer.

Curtin Matheson Scientific to distribute Bard BTA Test; Three-minute test provides revolutionary tool for bladder cancer management

The clinical trial, conducted in Germany, France and England, compared the BTA Test to voided urine cytology and bladder wash cytology in patients suspected of having bladder cancer.

European study confirms superiority of Bard BTA over cytology in new patient population; Results of multicenter clinical trial presented at urology conference

The Bard BTA test is used for the qualitative measurement of bladder tumor associated analytes in human urine to aid in the management of bladder cancer patients.

Bard bladder cancer test receives FDA approval

Her fitness and BTA tests were assessed at the Matt Roberts Centre, One Aldwych, London WC2 (020-7300 0600).

MOT your body; Fancy a new bod for Christmas? Your wish is our command. Our experts are here to play Santa with the kind of professional advice that guarantees you'll be sparkling like the fairy on top of the tree..